Health Trials

SMARCB1-Deficient Malignancies

1

Review clinical trials related to SMARCB1-Deficient Malignancies. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

To find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).

Participants needed: 40
Trial details
Phase: Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 18, 2026Locations: 1
Eligibility criteria

Participants with locally advanced or metastatic RMC (RMC cohort) or ES (ES coho... [+18]

Participants must not have any other malignancies within the past 2 years except... [+28]

Read more